MANAGEMENT OF PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION FOLLOWING A FIRST CLINICALLY RELEVANT BLEED: A REAL-WORLD STUDY BASED ON UK CLINICAL PRACTICE RESEARCH DATALINK - HOSPITAL EPISODE STATISTICS DATA

被引：0
|
作者：
Ramagopalan, Sreeram
Samnaliev, Mihail
McDonald, Laura
Hill, Nathan
Stynes, Gillian
Lefevre, Cinira
Sammon, Cormac
Squibb, Bristol-Myers
机构：
[1] Bristol Myers Squibb, Uxbridge, Middx, England
[2] PHMR Ltd, London, England
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2018年 / 71卷 / 11期
关键词：
D O I：
10.1016/S0735-1097(18)30867-2
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A326
引用
收藏
页码：326 / 326
页数：1
相关论文
共 50 条
  • [1] Suboptimal Management of Patients with Non-valvular Atrial Fibrillation: Real-world Clinical Setting
    Lau, Wallis C. Y.
    Chan, Esther W.
    Wong, Ian C. K.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 : 380 - 380
  • [2] Dabigatran in 'real-world' clinical practice for stroke prevention in patients with non-valvular atrial fibrillation
    Potpara, Tatjana S.
    THROMBOSIS AND HAEMOSTASIS, 2015, 114 (06) : 1093 - 1098
  • [3] The management of anticoagulant treatment in non-valvular atrial fibrillation real-world patients
    Valeriani, Emanuele
    Ageno, Walter
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2019, 62 : 7 - 8
  • [4] The Unmet Needs of Antithrombotic Treatment in Patients with Non-Valvular Atrial Fibrillation in Real-World Clinical Practice
    Lau, W. C. Y.
    Chan, E. W.
    Liu, K.
    Wong, I. C. K.
    DRUG SAFETY, 2014, 37 (10) : 854 - 854
  • [5] CHOICE OF ANTITHROMBOTIC DRUG IN NON-VALVULAR ATRIAL FIBRILLATION PATIENTS IN REAL-WORLD PRACTICE
    Citarella, A.
    Cammarota, S.
    Creazzola, S.
    De Marino, C.
    Izzo, P.
    La Bella, G.
    Piscitelli, R.
    Romagnuolo, F.
    Esposito, E.
    Guida, A.
    VALUE IN HEALTH, 2015, 18 (07) : A380 - A380
  • [6] Persistence of Dabigatran Versus Warfarin Therapy in Patients with Non-valvular Atrial Fibrillation in the Real-world Clinical Practice
    Lau, Wallis C. Y.
    Chan, Esther W.
    Wong, Ian C. K.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 : 382 - 382
  • [7] Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in "real-world" clinical practice
    Li, Xiaoyan
    Deitelzweig, Steve
    Keshishian, Allison
    Hamilton, Melissa
    Horblyuk, Ruslan
    Gupta, Kiran
    Luo, Xuemei
    Mardekian, Jack
    Friend, Keith
    Nadkarni, Anagha
    Pan, Xianying
    Lip, Gregory Y. H.
    THROMBOSIS AND HAEMOSTASIS, 2017, 117 (06) : 1072 - 1082
  • [8] The comparative safety and effectiveness of antithrombotic treatment in non-valvular atrial fibrillation following a first clinically relevant bleed: an observational study in the United Kingdom
    Ramagopalan, S.
    Sammon, C. J.
    Samnaliev, M.
    Hill, N.
    Stynes, G.
    Lefevre, C.
    McDonald, L.
    EUROPEAN HEART JOURNAL, 2018, 39 : 820 - 820
  • [9] STROKE PROPHYLAXIS MANAGEMENT STRATEGIES IN NON-VALVULAR ATRIAL FIBRILLATION (NVAF) PATIENTS: A REAL-WORLD EXPERIENCE
    Siddiqui, Safia
    Davis, Karrie
    Heard, Thomas
    Glover, Jon
    Hartman, Timothy
    Patel, Amar
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (18) : 1505 - 1505
  • [10] Cost-effectiveness of apixaban in non-valvular atrial fibrillation (NVAF) based on effectiveness data from a Spanish study in clinical practice (real-world evidence)
    Anguita, Manuel
    Marin, Francisco
    Soto, Javier
    de Cabo, Susana Fernandez
    Rubio-Rodriguez, Dario
    Rubio-Terres, Carlos
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2025, 23 (1-2) : 45 - 51
12345